Minaris, a Philadelphia-based global cell and gene therapy CDMO and biosafety testing provider, has hired Haylee Erickson as Director, Business Development, CDMO Services, the company announced on November 11, 2026. Erickson brings more than two decades of life sciences sales and business development experience across cell and gene therapy, viral vectors, plasmid DNA and strategic account management. She’ll support sponsors across the Central and Pacific Northwest U.S. regions.
Minaris said Erickson brings a strong technical foundation and “a practical understanding of what advanced therapy developers need from a CDMO partner.” In her new role, she’ll support both the company’s Cell Therapies and Viral Vectors CDMO services, helping sponsors advance programs from early development toward clinical and commercial manufacturing.
About Haylee Erickson
Erickson most recently served as Senior Director, Business Development at AGC Biologics. Before that, she spent three years at Aldevron, first as Senior Account Manager for the West Coast and then as Global Strategic Account Manager. There she built partnerships with companies in the RNA, cell and gene therapy space and drove significant revenue growth. She previously held senior business development roles at Exothera and Cytovance Biologics, and was a Business Development Executive for plasmid DNA CDMO services at Thermo Fisher Scientific.
Earlier in her career, Erickson was a Senior Life Science Specialist at Lonza, selling consumables and capital equipment across a six-state territory. She also held sales roles at Thermo Fisher Scientific and as a BioPharmaceutical Account Manager at bioMérieux. She began her career as a microbiologist at LABS Inc., performing testing, R&D studies and validation work for products used in organ and tissue transplantation.
Erickson holds a B.S. in Medical Microbiology and Bacteriology from Idaho State University and earned a Negotiation Mastery certificate from Harvard Business School.
About Minaris
Minaris is a global cell and gene therapy CDMO and multimodality biosafety testing provider with more than 25 years of experience developing, manufacturing and testing therapies. The company operates through three business units: Minaris Cell Therapies, Minaris Viral Vectors and Minaris Advanced Testing. With five global sites across three continents, Minaris supports partners from early development through clinical and commercial manufacturing.
